Aurobindo Pharma Ltd experienced a decline in its share prices on 17th May 2019. The company reported to the exchanges about three of its plants classified as Official Action Indicated...
Aurobindo Pharma Ltd, OAI, Official Action Indicated, US Food and Drug Administration, US generic drug litigation, USFDA
0 Comment
